AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01113-06v1
51/4/1534    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richter, E.
Right arrow Articles by Hillemann, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richter, E.
Right arrow Articles by Hillemann, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2007, p. 1534-1536, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01113-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

First Linezolid-Resistant Clinical Isolates of Mycobacterium tuberculosis{triangledown}

Elvira Richter, Sabine Rüsch-Gerdes, and Doris Hillemann*

Forschungszentrum Borstel, National Reference Center for Mycobacteria, D-23845 Borstel, Germany

Received 4 September 2006/ Returned for modification 10 October 2006/ Accepted 10 January 2007


   ABSTRACT
Top
 Abstract
Text
 References
 
Linezolid resistance was found in 4 (1.9%) of 210 multidrug-resistant Mycobacterium tuberculosis strains. The MICs of linezolid were 4 µg/ml (one strain) and 8 µg/ml (three strains). Since no mutations were detected in potential target genes, the mechanism of resistance remains unclear.


   TEXT
Top
 Abstract
 Text
References
 
The ongoing global burden of tuberculosis (TB) and the increasing problem of multidrug-resistant (MDR) TB (resistant to at least isoniazid and rifampin) have led to the increased use of second-line anti-TB drugs. Linezolid is a recently approved antituberculosis drug belonging to a new class of antibiotics, the oxazolidinones (1). Early studies have shown that linezolid is a protein synthesis inhibitor that interacts with domain V of the 23S rRNA (9). This domain is also the binding site for chloramphenicol, macrolides, and lincosamides, but the lack of cross-resistance between oxazolidinones and other antibiotics supports evidence for a novel mechanism of action (5, 10-12).

To date, linezolid-resistant Mycobacterium tuberculosis clinical strains seem to be rare. In this study, 210 MDR M. tuberculosis strains sent to the German National Reference Laboratory for Mycobacteria from 2003 to 2005 were examined for linezolid resistance, using the BACTEC 460 and BACTEC MGIT 960 systems (Becton Dickinson Diagnostic Systems, Sparks, MD). Linezolid susceptibility testing was performed at 1 µg/ml, as this was the critical concentration determined in a previous investigation (7). Of the 210 strains tested, 4 (1.9%) exhibited linezolid resistance, defined as an MIC of >1 µg/ml. The four patients harboring these strains were known to be infected with strains resistant to at least isoniazid, rifampin, streptomycin, and ethambutol (Fig. 1). The nonrelatedness of the strains was ascertained by the different origins of the patients, diverse susceptibility patterns of the strains, and different IS6110 patterns of the strains, which remained identical within each patient over the years. The reasons for the occurrence of linezolid resistance were determined by referring to the patients' treatment histories shortly before resistance was observed. In that period, patient 1 was treated with pyrazinamide (to which the strain was already resistant), cycloserine, capreomycin (three times weekly), and linezolid. Capreomycin was stopped after 2 months. Patient 2 was treated with a six-drug combination (rifabutin, ofloxacin, pyrazinamide, cycloserine, lamprene, and linezolid), although the strain was resistant to rifabutin and ofloxacin. Despite controlled treatment in a hospital, linezolid resistance evolved. Few data were available for patient 3. Within 2 years, the patient was admitted to several hospitals. During that time, linezolid resistance developed. Approximately one-half to 1 year before linezolid resistance was detected, patient 4 was treated as an outpatient with cycloserine, capreomycin (three times weekly), and linezolid. The possible causes for the development of resistance in these cases might be lack of compliance, intermittent treatment, and/or weaker tuberculostatic activities of second-line drugs.


Figure 1
View larger version (16K):
[in this window]
[in a new window]

  		FIG. 1. Diagrammatic representation of the time-dependent development of drug resistance in the four linezolid-resistant strains. The drugs for which resistance was determined over time are indicated in boxes. INH, isoniazid; RMP, rifampin; SM, streptomycin; PZA, pyrazinamide; EMB, ethambutol; OFX, ofloxacin; LEV, levofloxacin; LAM, lamprene; LIN, linezolid; PTH, protionamide; AK, amikacin; CM, capreomycin; RBT, rifabutin; MOX, moxifloxacin; CS, cycloserine. Arrows indicate drug susceptibility tests with a result of linezolid susceptibility, and asterisks specify susceptible parent strains that were chosen for MIC determinations.

 
To determine the levels of linezolid resistance, the MICs of all linezolid-resistant strains and their susceptible parent strains were determined. For the four resistant strains, the MICs were estimated to be 4 (patient 3) and 8 µg/ml (patients 1, 2, and 4). The MIC of the susceptible parent strains from patients 1, 2, and 4 and of an MDR control strain was estimated to be 0.5 µg/ml, while that of the susceptible parent strain from patient 3 and of M. tuberculosis H37 was 1 µg/ml. MICs were identical irrespective of the method used (BACTEC MGIT 960 or BACTEC 460).

Two relevant parameters for the efficiency of a drug are its concentration and duration at the site of action. In a pharmacokinetic study, the mean 12-h concentration of linezolid in the inflammatory fluid was 4.9 µg/ml, and peak levels were between 6 and 21 µg/ml in plasma and inflammatory fluid (3). The MICs estimated in that study shifted from 0.5 and 1 to 4 and 8 µg/ml, respectively, which may point out the clinical significance of these findings.

There were no obvious differences in the growth characteristics of linezolid-resistant and -susceptible strains after growth on Löwenstein-Jenssen medium, with (linezolid-resistant strains) or without linezolid.

To investigate whether the linezolid-resistant strains belonged to a certain genotype, real-time PCRs with all four linezolid-resistant strains and their respective susceptible parents were performed. Real-time PCR is able to distinguish between Beijing and non-Beijing genotype strains by targeting a specific deletion uniquely present in Beijing strains (4). Since two isolates and their respective susceptible parents were identified as Beijing genotypes (from patients 1 and 3) and the other two were identified as non-Beijing genotype M. tuberculosis strains, it can be stated that linezolid resistance is not restricted to one of the two groups.

To identify the mechanism of resistance, DNA sequencing of putative target genes was performed for all the linezolid-resistant strains and their respective susceptible parents. The sequences of the complete 23S rRNA gene, the rplV and rplD genes, coding for ribosomal proteins L4 and L22, the erm-37 gene, coding for a 23S rRNA methyltransferase, and a putative regulator, the whiB7 gene, were determined. The primers listed in Table 1 were used for amplification and sequencing. The alignment of all sequences revealed no alterations between susceptible or resistant strains or M. tuberculosis H37.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Primers used in the present study

 
Possible effects of efflux pump inhibitors could give the first hints of a resistance mechanism. Therefore, linezolid MICs of resistant strains were determined in the presence of the inhibitor reserpine (12 µg/ml) (6). Linezolid MICs were reduced only slightly, from 8 to 4 µg/ml and from 4 to 2 µg/ml. Reserpine alone showed no inhibitory effect on growth. Thus, aside from the first hint that efflux pumps could be involved in linezolid resistance, the mechanism remains unexplained. Sander and coworkers isolated Mycobacterium smegmatis class I and II linezolid-resistant mutants, suggesting different mechanisms of resistance (8). Class I mutants, with alterations in 23S rRNA, had high MICs of ≥64 µg/ml. Class II mutants had wild-type growth characteristics, unaltered peptidyl transferase activity, and MICs of 4 to 8 µg/ml (8). If similar mechanisms for the emergence of resistance are assumed for the isolated M. tuberculosis strains, then they could be classified as class II mutants (lacking mutations and having similar growth characteristics and MICs). Sander and coworkers proposed a nonribosomal resistance mechanism for class II mutants (8). Further studies on the functionality of the ribosomes of the linezolid-resistant M. tuberculosis strains, the investigation of potential reserpine-resistant efflux pumps, or a reduced input rate of the drug could elucidate the mechanism of linezolid resistance in M. tuberculosis.


   ACKNOWLEDGMENTS
 
We thank M. Pfohl, K. Ott, F. Schaefer, and T. Ubben, Forschungszentrum Borstel, Germany, for excellent technical assistance. Furthermore, we thank C. Barkhofen, Klinik Schillerhöhe, Germany, C. Göbel, Gesundheitsamt Karlsruhe, Germany, H.-P. Schmidt, Rangauklinik Ansbach, Germany, and I. Aumüller, AGES HumanMed Linz, Austria, for kindly providing the patients' data.


   FOOTNOTES
 
* Corresponding author. Mailing address: Forschungszentrum Borstel, National Reference Center for Mycobacteria, Parkallee 18, D-23845 Borstel, Germany. Phone: (49)-4537-188761. Fax: (49)-4537-188311. E-mail: dhillemann{at}fz-borstel.de Back

{triangledown} Published ahead of print on 22 January 2007. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Bozdogan, B., and P. C. Appelbaum. 2004. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 23:113-119.[CrossRef][Medline]
  2. Buriankova, K., F. Doucet-Populaire, O. Dorson, A. Gondran, J. C. Ghnassia, J. Weiser, and J. L. Pernodet. 2004. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 48:143-150.[Abstract/Free Full Text]
  3. Gee, T., R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise. 2001. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45:1843-1846.[Abstract/Free Full Text]
  4. Hillemann, D., R. Warren, T. Kubica, S. Rüsch-Gerdes, and S. Niemann. 2006. Rapid detection of Mycobacterium tuberculosis Beijing genotype strains by real-time PCR. J. Clin. Microbiol. 44:302-306.[Abstract/Free Full Text]
  5. Lin, A. H., R. W. Murray, T. J. Vidmar, and K. R. Marotti. 1997. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. 41:2127-2131.[Abstract]
  6. Pasca, M. R., P. Guglierame, E. De Rossi, F. Zara, and G. Riccardi. 2005. mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 49:4775-4777.[Abstract/Free Full Text]
  7. Rüsch-Gerdes, S., G. E. Pfyffer, M. Casal, M. Chadwick, and S. Siddiqi. 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol. 44:688-692.[Abstract/Free Full Text]
  8. Sander, P., L. Belova, Y. G. Kidan, P. Pfister, A. S. Mankin, and E. C. Böttger. 2002. Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations. Mol. Microbiol. 46:1295-1304.[CrossRef][Medline]
  9. Shinabarger, D. 1999. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs 8:1195-1202.[CrossRef][Medline]
  10. Wolter, N., A. M. Smith, D. J. Farrell, W. Schaffner, M. Moore, C. G. Whitney, J. H. Jorgensen, and K. P. Klugman. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49:3554-3557.[Abstract/Free Full Text]
  11. Xiong, L., P. Kloss, S. Douthwaite, N. M. Andersen, S. M. Swaney, D. L. Shinabarger, and A. S. Mankin. 2000. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J. Bacteriol. 182:5325-5331.[Abstract/Free Full Text]
  12. Zurenko, G. E., J. K. Gibson, D. L. Shinabarger, P. A. Aristoff, C. W. Ford, and W. G. Tarpley. 2001. Oxazolidinones: a new class of antibacterials. Curr. Opin. Pharmacol. 1:470-476.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, April 2007, p. 1534-1536, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01113-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01113-06v1
51/4/1534    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richter, E.
Right arrow Articles by Hillemann, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richter, E.
Right arrow Articles by Hillemann, D.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS